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OBJECTIVE—We hypothesized that intranasal insulin (I-I) de-
livery targets the nervous system while avoiding potential ad-
verse systemic effects when compared with subcutaneous insulin
(S-I) for experimental streptozotocin-induced diabetic peripheral
neuropathy (DPN).
RESEARCH DESIGN AND METHODS—I-I or S-I at 0.87 IU
daily or placebo were delivered in separate cohorts of diabetic
and nondiabetic CD1 mice during 8 months of diabetes. Radio-
labeled insulin detection was used to compare delivery and
biodistribution for I-I and S-I. Biweekly behavioral testing and
monthly electrophysiological and quantitative studies assessed
progression of DPN. At and before end point, morphometric
analysis of DRG, peripheral nerve, distal epidermal innervation,
and speciﬁc molecular markers were evaluated.
RESULTS—Radiolabeled I-I resulted in more rapid and concen-
trated delivery to the spinal cord and DRG with less systemic
insulin exposure. When compared with S-I or intranasal placebo,
I-I reduced overall mouse mortality and sensory loss while
improving neuropathic pain and electrophysiological/morpholog-
ical abnormalities in diabetic mice. I-I restored mRNA and
protein levels of phosphoinositide 3-kinase/Akt, cyclic AMP
response element–binding protein, and glycogen synthase kinase
3 to near normal levels within diabetic DRGs.
CONCLUSIONS—I-I slows the progression of experimental
DPN in streptozotocin mice, avoids adverse effects associated
with S-I treatment, and prolongs lifespan when compared with
S-I. I-I may be a promising approach for the treatment of DPN.
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T
he most common form of peripheral nervous
system (PNS) disease complicating diabetes
mellitus is diabetic symmetric sensorimotor
polyneuropathy (DPN) (1,2). Diabetic PNS is
subject to behavioral, electrophysiological, and morpho-
logical changes within peripheral nerve axons, the dorsal
root ganglion (DRG), and epidermal nerve ﬁbers (2–4).
Although considered an “end-stage” complication, DPN
may occur early and may involve children with diabetes
(5).
Clinical intervention trials in both type 1 and type 2
diabetes have demonstrated that chronic hyperglycemia
has a strong association with the prevalence of com-
plications (6,7). Beyond chronic hyperglycemia, other
commonly hypothesized mechanisms relevant for path-
ogenesis of DPN include excessive sorbitol-aldose re-
ductase pathway ﬂux (8), protein kinase C isoform(s)
overactivity (9), increased oxidative and nitrative stress
(10), microangiopathy (11), and advanced glycation end
products and their receptor (12,13). An important mecha-
nism of DPN may also relate to impaired availability,
action, or uptake of growth factors necessary to support
peripheral neurons (3,4,14,15). For diabetic neuropathy,
modiﬁcations in neurotrophin levels or evidence of a
supportive role have been identiﬁed for many neurotro-
phin family members (14). An important neurotrophic
factor critical in supporting peripheral neurons, and dimin-
ished in diabetes mellitus, is insulin. Both insulin and
IGF-1 are important for neuronal survival and phenotypic
expression in DRG neurons, neuritic outgrowth through
speciﬁc insulin receptor or IGF-1 receptor-mediated sig-
naling pathways within the adult sensory neuron (4,16,17).
Insulin binds to the insulin receptor  subunit, promot-
ing tyrosine autophosphorylation of the  subunit and
subsequent phosphorylation of cellular substrates, in-
cluding the insulin receptor substrate (IRS) proteins and
Shc (18). Phosphorylation of IRS-1 or IRS-2 (18) creates
an active signaling complex involving phosphatidylino-
sitol 3-kinase (PI3K), Akt, and the downstream effectors
cyclic AMP response element–binding protein (CREB)
and glycogen synthase kinase 3 (GSK-3), among other
molecules (19).
In an experimental type 1 diabetes model of DPN, we
hypothesized that a novel form of direct neuronal
long-term insulin replacement therapy could slow DPN
progression. Previous experiments have demonstrated
that direct intrathecal insulin is capable of reversing
features or preventing progression of DPN (3,4,17). We
designed experiments using behavioral and electrophys-
iological testing to assist in delineating insulin’s trophic
and antihyperglycemic effects in DPN using intranasal
insulin (I-I) delivery to target insulin to the nervous
system without signiﬁcant alteration of blood levels of
insulin or glucose (20). Intranasal delivery was ﬁrst
developed to bypass the blood-brain barrier and directly
target growth factors and other therapeutic agents to
the central nervous system (20) with travel along both
olfactory and trigeminal neural conduits within extra-
cellular pathways exclusive of axonal transport (21).
Proteins as large as 27 kDa, including IGF-1, have been
successfully delivered to the brain using this method
(21) in rodents (22) and humans (23). Our primary goal
was to determine efﬁcacy of I-I intervention, but we also
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ventions used as secondary end points.
RESEARCH DESIGN AND METHODS
We studied a total of 484 male CD1 wild-type mice with initial weight of 20 to
30 g housed in plastic sawdust covered cages with a normal light-dark cycle
and free access to mouse chow and water. In all cases, mice were raised and
studied in strict pathogen-free environments. All protocols were reviewed and
approved by the institutional animal care and use committee at Regions
Hospital (21 mice, experiment 1) and the University of Calgary Animal Care
Committee using the Canadian Council of Animal Care guidelines (463 mice,
experiment 2). Mice were anesthetized with pentobarbital (60 mg/kg) before
all procedures. At the age of 1 month, 304 mice were injected with strepto-
zotocin (STZ) (Sigma, St. Louis, MO) intraperitoneally once daily for each of
3 consecutive days with doses of 60 mg/kg, 50 mg/kg, and then 40 mg/kg with
the remaining 180 mice injected with carrier (sodium citrate) for 3 consecu-
tive days. Studies using harvested tissues occurred after 1 month (36 diabetic
mice, 30 nondiabetic mice), 3 months (48 diabetic mice, 30 nondiabetic mice),
5 months (60 diabetic mice, 30 nondiabetic mice), and 8 months (160 diabetic
mice, 90 nondiabetic mice).
Whole blood glucose measurements were performed monthly with punc-
ture of the tail vein and a blood glucometer (OneTouch Ultra Meter; LifeScan
Canada, Burnaby, BC, Canada). Hyperglycemia was veriﬁed 1 week after STZ
injections with a fasting whole blood glucose level of 16 mmol/l or greater
(normal 5–8 mmol/l), our deﬁnition for experimental diabetes. All animals
were weighed monthly. Mice were followed and harvested at 1, 3, 5, or 8
months of diabetes (9 months of life). Mice that did not develop diabetes
were excluded from further assessment.
Animals were inspected twice daily and examined for signs of depressed
level of consciousness, ataxia, or general malaise. When such signs were
identiﬁed, whole blood glucose testing was performed with a measurement of
less than 3.5 mmol/l deﬁned to represent hypoglycemia. No intervention was
performed at any time with regard to additional insulin, glucose, or ﬂuid
delivery. In situations in which the mouse was obviously ill, euthanasia was
performed. In circumstances in which severe hyperglycemia was found (33
mmol/l) in an ill mouse, euthanasia was performed.
We studied cohorts with a maximum of eight mice in each group initially as
a result of resource limitations. After the initial cohorts containing eight mice
each were studied, a second cohort was used to obtain additional mouse data
for mouse cohorts with higher levels of mortality. For any animal that
experienced mortality after the 20-week point of the sensorimotor studies, the
data were carried through using the last obtainable data point.
In this work, delivery of subcutaneous saline is indicated as “S-S,”
subcutaneous insulin as “S-I,” intranasal saline as “I-S,” and intranasal insulin
as “I-I.”
Experiment 1: pharmacokinetic studies of intranasal or subcutaneous
delivery.
125I-labeled I-I administration was performed to determine distribu-
tion of intranasally delivered insulin in 21 nondiabetic mice. Before experi-
mentation, animals were acclimated for handling during awake intranasal
delivery for 2 weeks.
125I-labeled I-I was provided to 12 CD1 mice (male, 6–8
weeks; Charles River) and
125I-labeled S-I was provided to nine mice under
pentobarbital anesthesia (60 mg/kg). Insulin (Humulin R; Eli Lilly, Toronto,
Canada) with an initial concentration of 100 units/ml or 4033.98 mg/ml was
dissolved in PBS and custom-labeled with
125I (GE Healthcare, Piscataway,
NJ). Radiolabeled insulin solution contained 344.3 uCi/g at synthesis.
125I-
labeled I-I delivery was performed in a fume hood behind a lead-impregnated
shield with anesthetized mice placed supine. A mixture of
125I insulin (15.8
Ci) and unlabeled insulin (3.3 g) were administered as I-I or S-I.
125I I-I was
delivered as eight 3-l drops with an Eppendorf pipette over alternating nares
every 2 min for a total volume of 24 l. For subcutaneous delivery,
125I S-I was
delivered with a single subcutaneous injection of 24 l in a fume hood behind
a lead-impregnated shield.
At each of 1, 2, and 6 h after
125I I-I or S-I delivery, cardiocentesis was
performed to extract blood followed by euthanasia using transcardial perfu-
sion using 120 ml of 4% paraformaldehyde under anesthesia. To quantify
125I
distribution, portions of the nervous systems were harvested along with
blood, urine, lymphatic, and visceral organ structures. Olfactory epithelium
and trigeminal nerve were examined as a result of their role in intranasal
delivery into the nervous system and cerebrospinal ﬂuid. Gamma signal was
quantiﬁed in each tissue using a Packard Cobra II auto-gamma counter
(PerkinElmer Life and Analytical Sciences, Waltham, MA). Concentrations of
125I insulin were calculated based on the gamma counting data, tissue weight,
speciﬁc activity of the insulin administered, and measured standards.
Experiment 2: daily intranasal and subcutaneous insulin delivery
studies. Daily I-I (Humulin R; Eli Lilly) and intranasal saline (I-S) was
administered to either diabetic or nondiabetic male CD1 mice after a 1-week
training period immediately after STZ injection using only intranasal saline for
accustoming mice before diabetes veriﬁcation. Although each mouse was held
in a supine position while in neck extension, a total of 24 l containing either
a total of 0.87 IU of insulin or 0.9% saline only was provided as four drops of
6 l each through Eppendorf pipette over alternating nares every 1 min. Daily
S-I (0.87 IU) (Humulin R) and S-S were also administered daily to either
diabetic or nondiabetic male CD1 mice at the same dose. All therapies began
immediately after conﬁrmation of presence of diabetes for each cohort. In the
ﬁrst week, daily glucometer testing was performed for all mice followed by
once-monthly testing and during times of illness.
We attempted to use other control groups but found their usefulness to be
limited in each case. The delivery of S-I by a sliding scale approach requiring
daily whole blood glucose sampling through repeated punctures or the use of
a protected venous catheter led to intolerable rates of infection and/or tail
amputation, so the morbidity accrued with this procedure was deemed
unacceptable and a potential confounder with any behavioral studies. Deliv-
ery of reduced subcutaneous doses of insulin failed to modify glycemic levels.
Therefore, we selected the S-I dose to be equivalent to I-I dosing (0.87 IU) for
the cohorts studied.
Experiment 2a: electrophysiology during intranasal and subcutaneous
insulin delivery studies. Electrophysiological assessment of sciatic nerve
function was performed as previously described (13) under halothane anes-
thesia. Initial baseline studies were carrier out before STZ or carrier injec-
tions; no signiﬁcant difference between groups was identiﬁed. Of all cohorts of
mice receiving I-I, S-I, I-S, or S-S, both diabetic and nondiabetic, at least ﬁve
mice in each group underwent monthly electrophysiological testing beginning
before induction of diabetes and after 1, 2, 4, 6, and 8 months of diabetes. For
orthodromic sensory conduction studies, the sural nerve was used with a ﬁxed
distance of 30 mm from platinum subdermal stimulation needle electrodes
(Grass Instruments, Astro-Med, West Warwick, RI) to the sciatic notch where
recording electrodes were placed to measure the sensory nerve action
potential (SNAP) amplitude and sensory nerve conduction velocity (SNCV).
Near-nerve temperature was kept constant during testing at 37  0.5°C using
a heating lamp.
Experiment 2b: behavioral testing during intranasal and subcutaneous
insulin delivery studies. A total of 10 mice in each cohort had behavioral
testing performed twice monthly to evaluate mechanical and thermal sensa-
tion. A 2-week training period was performed to acclimatize mice to the
procedure immediately after STZ injections and during diabetes veriﬁcation.
Mice were placed in a Plexiglas cage on a glass plate (for thermal testing) or
on a plastic mesh ﬂoor (for tactile testing) and were allowed to acclimate for
at least 5 min before recording in all cases. Thermal sensation was tested
using the Hargreaves apparatus (24). In brief, a radiant heat source was
applied individually to the middle of either hind paw for up to 60 s with the
latency (seconds) to withdrawal measured. Heating rate ramped from 30 to
58°C over 60 s in consistent fashion on each occasion. Paws were inspected
before and after thermal testing to ensure that no evidence of thermal damage
was present. There were 5-min intervals provided between a total of three
trials performed during the same day. To quantify mechanical sensitivity of the
foot, withdrawal in response to a stimulus consisted of sequentially smaller
von Frey ﬁlaments (25). Five trials were performed at each ﬁlament size with
a total of three or more withdrawals to up-and-down movements indicating
sensitivity at the smallest positive ﬁlament size. Mechanical and thermal
testing was performed on identical days with an interval of at least 1 h
between the two tests.
Other procedures and testing. Harvesting of tissues and their subsequent
morphometric processing and analysis along with quantiﬁcation of epidermal
ﬁbers and all other molecular testing (Western immunoblotting, polymerase
chain reactions, and electrophoretic mobility shift assays) have been de-
scribed in detail in an online appendix (available at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-1287/DC1).
All statistical comparisons were intended between the following groups:
diabetic I-I and S-I; diabetic I-I and I-S; diabetic I-I and control I-I; diabetic S-I
and S-S; diabetic S-I and control S-I; control I-I and S-I; control I-I and I-S; and
control S-I and S-S. Comparison testing was not performed between other
grouped cohorts with Bonferroni corrections applied as appropriate for these
group comparisons.
Data collected in the groups were expressed as mean  SE in all cases.
Data from each individual mouse were used to obtain means in each case.
One-way matched/unmatched ANOVA and Student’s t tests were performed to
compare means between diabetic and control groups. For immunohistochem-
istry comparisons demonstrated as low/medium/high intensity, the individual
values were compared using unmatched ANOVA testing. Also, AUC statistical
testing was performed for behavioral testing performed and was calculated
using the trapezoidal method. Again, only the groups intended to have
statistical comparisons were analyzed as such. Correlational relationships for
AUC were tested using multiple linear regression analysis. For the purposes of
G. FRANCIS AND ASSOCIATES
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abetic) group was used as a control value with subsequent comparisons to
other diabetic groups for the molecular test studied; Bonferroni corrections
were made as appropriate depending on the number of relevant comparisons.
RESULTS
Experiment 1: distribution of administered insulin.
At 1 h after I-I or S-I delivery, insulin concentrations were
higher within cervical spinal cord, DRGs, and spinal dura
with I-I delivery (Fig. 1). Insulin concentrations in blood
were substantially higher after S-I delivery (850 greater),
but insulin concentrations within kidney, liver, and lung
were higher after I-I delivery.
At 6 h after I-I or S-I delivery, insulin concentrations
were higher in DRGs and spinal dura after S-I delivery
compared with I-I delivery (Fig. 1). After 6 h, blood
concentrations of insulin were higher after I-I delivery
with this peak detected at 6 h. Insulin concentrations in
systemic organs were now higher after S-I delivery. When
2-h data are considered, I-I delivery led to peaks in insulin
concentration within DRGs and systemic organs after 1 h
and peaks in blood concentrations of insulin after 6 h. S-I
delivery, in contrast, led to peaks in insulin concentration
at DRG and systemic organs after 6 h, whereas blood
concentrations peaked after 1 h. Blood concentrations of
insulin after S-I delivery peaked at a value nearly 1,000
the peak value obtained with I-I delivery.
Mice receiving I-I treatment maintained good health
throughout the 1-, 2-, and 6-h monitoring periods before
FIG. 1. Detection of radiolabeled insulin after 1 and6ho fboth I-I and S-I. Initial blood and organ insulin levels were lower than those achieved
with S-I (A; after 1 h). At 6 h after delivery (B), I-I was associated with increased blood levels, and S-I was more readily identiﬁed in nervous
tissues. Signiﬁcant differences were determined by matched Student’s t tests, with an asterisk indicating a signiﬁcant difference (P < 0.05)
between the I-I and S-I delivery techniques for each tissue (n  4 mice in each mouse cohort for each time point).
INTRANASAL INSULIN AND DIABETIC NEUROPATHY
936 DIABETES, VOL. 58, APRIL 2009being euthanized, whereas S-I delivery led to more fre-
quent development of hypoglycemia-induced illness, in-
cluding death, and also to reduced consciousness levels in
many mice.
Experiment 2: diabetes model. After STZ injection,
mice developed diabetes within 2 weeks in greater than
85% of animals, and in each case, diabetes was maintained
over the length of the study. Diabetic mice were smaller
than nondiabetic mice within 1 month after STZ injection,
and diabetic mice had smaller body weights throughout
life (Table 1); diabetic mice receiving I-I maintained
weight better than the cohort receiving I-S. Hyperglycemia
was identical in mice receiving I-I or I-S, but S-I mice had
more documented hyperglycemia and more episodes of
illness or death associated with conﬁrmed hypoglycemia
(Table 1). Mouse glycated hemoglobin was increased in all
diabetic mice after more than 9 months of life and was
identical between I-I and I-S mice but was reduced in
surviving S-I mice (Table 1). The mortality rate in
diabetic mice was signiﬁcantly higher than in nondia-
betic mice, although diabetic I-I mice had improved
mortality relative to diabetic I-S, diabetic S-S, and diabetic S-I
mice (Table 1).
Experiment 2: impact of intranasal insulin on senso-
rimotor behavioral data. Before induction of diabetes,
there were no baseline differences in sensory behavior
testing between any of the mouse cohorts identiﬁed. All
diabetic mice developed tactile allodynia after 5 to 7
weeks of diabetes when compared with nondiabetic mice
(Fig. 2). Diabetic I-I mice developed less allodynia in the
ﬁrst 3 months of diabetes (Fig. 2) as compared with the
other diabetic cohorts. In the later stages of diabetes, I-I
mice had less tactile sensory loss than other diabetic
mouse cohorts, although diabetic S-I mice had greater
maintenance of sensation for tactile stimuli than diabetic
mice receiving S-S or I-S (Fig. 2). During serial thermal
testing, each cohort of diabetic mice also developed
thermal hypersensitivity when compared with nondiabetic
mice after several weeks, earlier than identiﬁed in other
species or mouse strains (Fig. 2). However, diabetic I-I
mice demonstrated less hypersensitivity in the early stages
of diabetes and maintained thermal sensation better in the
later stages of diabetes. Diabetic S-I mice had less thermal
sensory loss in the later stages of diabetes (Fig. 2) when
compared with diabetic mice receiving S-S and S-I. Within
the ﬁrst 20 weeks, AUC measurements were statistically
different for diabetic I-I mice as compared with other
diabetic mouse cohorts for both tactile and thermal test-
ing, and all diabetic cohorts had thermal hypersensitivity
and tactile allodynia when compared with nondiabetic
mice (Fig. 2).
Experiment 2: impact of intranasal insulin on elec-
trophysiology. Before induction of diabetes, there were
no baseline electrophysiological differences between any
of the mouse cohorts identiﬁed. Sensory amplitudes and
sensory conduction velocities demonstrated age-related
declines over time in both diabetic and nondiabetic co-
horts (Fig. 3, with more rapid declines in diabetes. Overall
reductions in SNAP amplitudes and in SNCV occurred in
diabetic mice relative to nondiabetic mice beginning after
2 to 3 months, similar to previous results (13). Protection
against declining SNAPs and SNCV occurred beginning at
3 to 4 months in diabetic I-I mice as compared with all
other cohort groups (Fig. 3) and slightly later in diabetic
S-I mice (Fig. 3). Overall, in comparison to S-S, I-S, and S-I
diabetic mice, diabetic I-I mice displayed signiﬁcant pro-
tection against electrophysiological deterioration in sen-
sory function.
Experiment 2: impact of intranasal insulin on periph-
eral nerve. In diabetic mice, sciatic nerves had axonal
atrophy without axonal loss identiﬁed (supplemental Ta-
ble 1), and sural nerves from diabetic mice developed a
loss of ﬁber density and axonal area (atrophy) relative to
nondiabetic controls (Table 2 and supplemental Fig. 1).
Diabetic I-I mice were protected from declines in sural
axon density and from axonal atrophy in both the sural
and sciatic nerves after 8 months of diabetes (Tables 2 and
3) when compared with diabetic S-I, S-S, and I-S mice
(supplemental Tables 1 and 2 and supplemental Fig. 1).
Diabetic sural and sciatic nerve myelin thickness was also
reduced after 8 months of diabetes (supplemental Tables 1
and 2) with some protection offered by I-I delivery.
Experiment 2: impact of intranasal insulin on dorsal
root ganglia. DRG neurons developed mild neuronal
atrophy and loss of density with exposure to long-term
diabetes (supplemental Fig. 2 and Table 3), except in the
case of diabetic I-I mice, in which no signiﬁcant loss in
neuronal density was identiﬁed, indicating neuronal pro-
tection (Table 3). Similarly, diabetic I-I mice again had
preservation of DRG neuronal size and density when
compared with diabetic I-S and diabetic S-S mice (supple-
mental Fig. 2 and Table 3). There was evidence of partial
protection among diabetic S-I mice (supplemental Fig. 2
and Table 3). DRG neurons from diabetic I-I mice had
elevated levels of PI3K, Akt, and pAkt mRNA and protein
(Fig. 4).
Experiment 2: impact of intranasal insulin on epider-
mal innervation. The hind footpad epidermal nerve ﬁber
density of all mouse cohorts with diabetes was reduced
compared with nondiabetic mice (Fig. 5). Overall, diabetic
I-I mice were protected from epidermal ﬁber loss (Fig. 5),
whereas diabetic S-I mice had better maintained epidermal
nerve ﬁber density than diabetic S-S or diabetic I-S mice by
the 8-month end point. The separate methods of analyses
for epidermal nerve ﬁber densities yielded similar results.
Experiment 2: impact of intranasal insulin on signal-
ing pathways. Quantiﬁcation of mRNA and protein for
Akt and PI3K demonstrated general downregulation in
diabetic tissues with at least partial reversal of both PI3K
and Akt mRNA and protein levels occurring in diabetic I-I
mice (Fig. 4) in DRG, but not in sciatic nerve. Diabetic I-I
mice also had partial protection from downregulation of
pGSK3, GSK3, and pCREB (Fig. 4). Finally, CREB
protein binding to DNA was identiﬁed to be depressed
with diabetes (supplemental Fig. 3) with partial resolution
in diabetic I-I mice.
DISCUSSION
I-I protected diabetic mice from behavioral, structural, and
molecular changes associated with DPN. We propose that
insulin’s neuroprotective effects on the PNS are the result
of restoration of the PI3K/Akt pathway components (Fig.
4). Additionally, I-I led to less mortality than S-I delivery
and provided greater protection against the effects of
long-term diabetes on the PNS.
Systemic and peripheral nervous system impact of
subcutaneous and intranasal insulin. Replacement of
insulin in a type I model of diabetes through either I-I or S-I
delivery led to improvements in behavioral, electrophysi-
ological, morphological, and molecular status (Figs. 2–5
and supplemental Figs. 1–3) related to diabetes. Paradox-
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INTRANASAL INSULIN AND DIABETIC NEUROPATHY
938 DIABETES, VOL. 58, APRIL 2009ically, S-I delivery in diabetic mice led to greater mortality
(Table 1), relating in part to episodes of hypoglycemia, a
complication avoided by I-I. Although S-I led to improved
glycated hemoglobin levels at ﬁnal end point, this effect
was not seen in diabetic I-I mice. These results suggest
that the beneﬁcial effects of I-I in diabetes are not primar-
ily related to corrections in hyperglycemia (Table 1).
Role of insulin as a neuroprotective trophic factor.
Insulin, a highly conserved peptide, has now emerged as a
key neurotrophic factor in the nervous system, a role that
is lost in type 1 diabetes. The major site of insulin’s
activity, the insulin receptor, is found in high concentra-
tions among DRG neurons and myelinated sensory root
ﬁbers and in lesser concentrations on myelinated anterior
FIG. 2. Tactile (A) and thermal (B) sensory testing data for sciatic nerve function in mice with or without diabetes. Signiﬁcant differences were
determined by multiple ANOVA tests, with an asterisk indicating a signiﬁcant difference (P < 0.0125 using Bonferroni corrections) between the
diabetic I-I mouse group and other diabetic mouse cohorts and with  indicating a signiﬁcant difference (nonmatched ANOVA tests; F-values
range between 1.08 and 11.76 for indicated groups and time points; df  3,5; n  8; P < 0.0125 using Bonferroni corrections) between the diabetic
S-I mouse group and diabetic S-S and diabetic I-S groups for the respective time points. AUC measurements also revealed greater values for
nondiabetic cohorts as compared with relevant diabetic cohorts in each case (P < 0.0125). AUC values were also greater for diabetic I-I mice for
the ﬁrst 20 weeks studied as compared with other diabetic cohorts (P < 0.0125) (n  6–8 mice in each mouse cohort for each time point). C,
control; D, diabetic; I-I, intranasal insulin; S-I, subcutaneous insulin; S-S, subcutaneous saline.
G. FRANCIS AND ASSOCIATES
DIABETES, VOL. 58, APRIL 2009 939root ﬁbers and in the ventral horn of the spinal cord
(16,26). Intrathecal insulin prevents degeneration and pro-
motes regeneration in injured peripheral nerve (16). Mean-
while, systemic or intrathecal insulin delivery prevents
diabetes-mediated electrophysiological changes (27),
whereas intrathecal insulin restores distal skin epidermal
innervation (17). In vitro, insulin exerts a direct neuritic
outgrowth effect through insulin receptors or perhaps
through crossactivation of IGF-1 receptors (28). Insulin’s
greatest impact appears to be at the level of the DRG,
where insulin may prevent a “dying-back” that begins in
the most distal epidermal ﬁbers (4,29).
FIG. 3. Sensory nerve conduction study data for sciatic nerves in mice with or without diabetes. Diabetic I-I mice had more successful
amelioration than diabetic S-I mice of decline of sensory nerve action potential (SNAP) amplitudes (A) and sensory nerve conduction velocities
(SNCV) (B) when compared with other diabetic cohorts. Signiﬁcant differences were determined by multiple ANOVA tests, with an asterisk
indicating signiﬁcant difference (P < 0.0125 using Bonferroni corrections) between the diabetic I-I mouse group and other diabetic mouse
cohorts and with  indicating signiﬁcant difference (P < 0.0125 using Bonferroni corrections) between the diabetic S-I mouse group and diabetic
S-S and diabetic I-S groups for the respective time points (nonmatched ANOVA tests; F-values range between 0.98 and 6.44 for indicated groups
and time points; df  3,5; n  6–8 mice in each mouse cohort for each time point). C, control; D, diabetic; S-I, subcutaneous insulin; I-I, intranasal
insulin; S-S, subcutaneous saline.
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940 DIABETES, VOL. 58, APRIL 2009Insulin’s downstream signaling pathways. Insulin
stimulation upregulates protein-tyrosine phosphoryla-
tion (30) through downstream activation of IRS-2 (18).
Insulin also modulates the inner mitochondrial mem-
brane potential through activation of the PI3K pathway
(31), stimulating phosphorylation of Akt and Akt sub-
strates such as CREB (32–35). PI3K promotes translo-
cation of voltage-dependent calcium channel currents to
the neurolemma in an Akt-dependent manner (36).
Activated Akt is important for sensory neurite extension
and branching (37), and the PI3K–Akt pathway has a
positive regulatory effect on myelin-associated glyco-
protein (MAG) expression in Schwann cells, Schwann
cell differentiation (38), and promotion of myelination
(39) through Schwann cell biosynthesis of fatty acids
(40). Similar to insulin, IGF-I also activates the PI3K/Akt
pathway (41), leading to phosphorylation of Akt effec-
tors, including CREB and GSK-3 (19). IGF-I also leads
to accumulation of pAkt within DRG neuronal nuclei
and increases CREB-mediated transcription (19). In our
studies, prevention of downregulation of PI3K/Akt (Fig.
4) in murine DRG was associated with amelioration of
behavioral, electrophysiological, and morphological
changes pertaining to diabetes.
CREB is also a neuroprotective molecule; CREB
phosphorylation inhibits apoptosis in embryonic neu-
rons (42), whereas the loss of CREB results in impaired
axonal growth (43). Meanwhile, GSK-3, downstream of
PI3K/Akt, is a neuron-speciﬁc promoter of apoptosis in
DRG neurons when it is active (nonphosphorylated
TABLE 2
Morphological properties of sural nerves in nondiabetic and
diabetic nerves from mice receiving intranasal or subcutaneous
insulin or saline after 1 and 8 months of diabetes
Physical property n
1 month of
diabetes
8 months of
diabetes
Axonal ﬁber density
(per mm
2)
Nondiabetic I-I mice 4–6 18,024  136 17,522  124
Nondiabetic I-S mice 4–6 18,122  142 17,113  132
Nondiabetic S-I mice 4–6 18,098  138 17,222  128
Nondiabetic S-S mice 4–6 18,055  151 17,151  147
Diabetic I-I mice 4–5 18,104  157 16,377  168*
Diabetic I-S mice 4 18,085  164 14,982  175*
Diabetic S-I mice 4–5 18,063  161 15,522  115*
Diabetic S-S mice 4–5 18,002  168 14,916  172*
Axonal area (m
2)
Nondiabetic I-I mice 4–6 33.6  0.8 28.7  0.7
Nondiabetic I-S mice 4–6 32.9  0.7 27.4  0.8
Nondiabetic S-I mice 4–6 32.9  0.8 27.6  0.7
Nondiabetic S-S mice 4–6 33.4  0.7 27.3  0.5
Diabetic I-I mice 4–5 33.8  0.7 26.8  0.6*†
Diabetic I-S mice 4 32.7  0.7 23.2  0.8*
Diabetic S-I mice 4–5 33.1  0.8 24.3  0.7*
Diabetic S-S mice 4–5 32.6  0.8 23.6  0.7*
Axonal diameter (m)
Nondiabetic I-I mice 4–6 5.34  0.20 4.92  0.15
Nondiabetic I-S mice 4–6 5.12  0.21 4.77  0.14
Nondiabetic S-I mice 4–6 5.28  0.20 4.98  0.14
Nondiabetic S-S mice 4–6 5.19  0.19 4.83  0.13
Diabetic I-I mice 4–5 5.18  0.16 4.34  0.11*†
Diabetic I-S mice 4 5.08  0.15 3.80  0.12*
Diabetic S-I mice 4–5 5.22  0.12 4.02  0.11*
Diabetic S-S mice 4–5 5.11  0.13 3.78  0.10*
Myelination thickness
(m)
Nondiabetic I-I mice 4–6 1.02  0.05 0.96  0.04
Nondiabetic I-S mice 4–6 1.03  0.05 0.93  0.05
Nondiabetic S-I mice 4–6 1.02  0.04 0.95  0.05
Nondiabetic S-S mice 4–6 1.04  0.05 0.94  0.04
Diabetic I-I mice 4–5 1.03  0.05 0.85  0.04*‡
Diabetic I-S mice 4 1.02  0.04 0.79  0.03*
Diabetic S-I mice 4–5 1.02  0.04 0.82  0.04*
Diabetic S-S mice 4–5 1.03  0.05 0.76  0.04*
Data are means  SEM. *Signiﬁcance between diabetic mice and their
nondiabetic intervention counterpart (D I-I versus C I-I, D I-S versus C
I-S, D S-I versus C S-I, and D S-S versus C S-S) (0.05, P  0.016)
(nonmatched ANOVA tests, F-values range between 0.85 and 0.02 for
indicated groups and time points, df  4,3, n  4–6). †Signiﬁcance with
comparison of D I-I mice to both D S-I and D I-S mice. ‡Signiﬁcance with
comparison of D I-I mice to D I-S mice using multiple ANOVA testing
with Bonferroni post hoc t test comparisons (0.05, P  0.016)
(nonmatched ANOVA tests, F-values range between 0.98 and 3.55 for
indicated groups and time points, df  5,4, n  4–6). D  diabetic; I-I 
intranasal insulin; C  control; I-S  intranasal saline; S-I  subcuta-
neous insulin; S-S  subcutaneous saline.
TABLE 3
Morphological properties of DRG neurons in nondiabetic and
diabetic mice receiving intranasal or subcutaneous insulin or
saline after 8 months of diabetes
Physical property n
8 months of
diabetes
Neuronal density (per mm
2)
Nondiabetic I-I mice 6 2,567  44
Nondiabetic I-S mice 6 2,516  37
Nondiabetic S-I mice 6 2,549  40
Nondiabetic S-S mice 6 2,517  41
Diabetic I-I mice 5 2,488  42*‡
Diabetic I-S mice 4 2,416  47*
Diabetic S-I mice 5 2,444  42*
Diabetic S-S mice 5 2,412  45*
Total neuronal numbers (per L5 DRG)
Nondiabetic I-I mice 6 2,675  68
Nondiabetic I-S mice 6 2,596  57
Nondiabetic S-I mice 6 2,609  70
Nondiabetic S-S mice 6 2,587  61
Diabetic I-I mice 5 2,252  62*†
Diabetic I-S mice 4 1,965  52*
Diabetic S-I mice 5 2,047  48*
Diabetic S-S mice 5 1,916  55*
Neuronal area (m
2)
Nondiabetic I-I mice 6 625  18
Nondiabetic I-S mice 6 611  17
Nondiabetic S-I mice 6 624  20
Nondiabetic S-S mice 6 614  19
Diabetic I-I mice 5 579  16*‡
Diabetic I-S mice 4 550  17*
Diabetic S-I mice 5 569  16*
Diabetic S-S mice 5 543  17*
Data are means  SEM. *Signiﬁcance between diabetic mice and
their nondiabetic intervention counterpart (D I-I versus C I-I, D I-S
versus C I-S, D S-I versus C S-I, and D S-S versus C S-S) (0.05, P 
0.016) (nonmatched ANOVA tests, F-values range between 0.88 and
8.76 for indicated groups and time points, DF  4,3, n  4–6).
†Signiﬁcance with comparison of D I-I mice to both D S-I and D I-S
mice. ‡Signiﬁcance with comparison of D I-I mice to D I-S mice using
multiple ANOVA testing with Bonferroni post hoc t test comparisons
(0.05, P  0.016) (nonmatched ANOVA tests, F-values range
between 0.98 and 3.55 for indicated groups and time points, df  5,4,
n  4–6). D  diabetic; I-I  intranasal insulin; C  control; I-S 
intranasal saline; S-I  subcutaneous insulin; S-S  subcutaneous
saline.
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DIABETES, VOL. 58, APRIL 2009 941state) (44). Phosphorylation of GSK-3 by Akt renders it
inactive, leading to antiapoptotic properties (44,45).
GSK-3 also regulates the transcriptional activities of
CREB (46,47) and may regulate gene expression and
activity of transcriptional factor binding to the MAG
promoter region (38). GSK-3 also promotes Schwann
cell differentiation, suggesting that the PI3K/Akt/GSK-3
pathway is crucial for initiation and possibly mainte-
FIG. 4. Quantitative RT-PCR identiﬁed marked downregulation for PI3K (A) and Akt (B) mRNA in DRG and sciatic nerve from diabetic mice with
protection in diabetic I-I mice in DRG but not in sciatic nerve. Downregulation of PI3K, Akt, and pAkt mRNA in diabetic DRG neurons was
complemented by downregulation of CREB, pCREB, GSK3, and pGSK3 protein within diabetic DRGs (C). Quantiﬁcation of three Western blots
for each mouse cohort identiﬁed downregulation of each of PI3K, Akt, pAkt, CREB, pCREB, GSK3, and pGSK3 protein for all diabetic DRG (D)
with partial protection in diabetic I-I mice. An asterisk indicates a signiﬁcant difference (P < 0.0125 after Bonferroni corrections) between
groups indicated by horizontal bars (nonmatched ANOVA tests; F-values range between 1.22 and 6.74 for indicated groups and time points; df 
2,3; n  5–6). All diabetes values were signiﬁcantly less than nondiabetes values (signiﬁcance not visually demonstrated). C, control; D, diabetic;
S-I, subcutaneous insulin; I-I, intranasal insulin; S-S, subcutaneous saline.
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pression (38). Thus, insulin may be important in
maintaining conduction velocities (Fig. 3) by direct
effects on Schwann cells. In our studies, I-I delivery was
associated with elevation of pCREB and pGSK-3 levels
and reversal of diabetes-associated suppression of
CREB-DNA binding within diabetic mouse DRGs (Fig. 4
and supplemental Fig. 3).
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FIG. 5. Epidermal footpads from mice with and without diabetes were assessed. The basement membrane and vasculature were identiﬁed with
immunohistochemistry for collagen type IV (red). Epidermal axons were identiﬁed with PGP 9.5 (green) for a control I-S mouse (A), control I-I
mouse (B), diabetic I-S mouse (C), and diabetic I-I mouse (D). Note the presence of epidermal end bulbs (arrows) in axons of diabetic mice.
Diabetes was associated with the loss of epidermal nerve ﬁbers (per epidermal area [E, hindfoot; F, forefoot] and length [G, hindfoot; H,
forefoot]), with partial preservation in diabetic I-I mice and less preservation in diabetic S-I mice (, C S-S; p, D S-S; , D S-I; f, D I-S; o, D I-I).
All measures of epidermal ﬁber density are listed as means  SEM. Asterisk indicates signiﬁcance with comparison of diabetic I-I and diabetic
I-S mice;  indicates signiﬁcance with comparison of diabetic I-I and diabetic S-I mice (nonmatched ANOVA tests, F-values range between 0.89
and 5.21 for indicated groups and time points, df  5,3, n  5–6). Bar  100 m. C, control; D, diabetic; I-S, intranasal saline; I-I, intranasal
insulin; S-I, subcutaneous insulin. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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athy. Intranasal administration allows insulin to bypass
the blood-brain barrier and enter the brain and spinal cord
parenchyma, as well as CSF, within 1 h. Its entry into the
nervous system and CSF likely occurs through extracellu-
lar bulk ﬂow transport along both olfactory and trigeminal
neural pathways and may use perivascular channels of
blood vessels entering the CNS (21). This method of
insulin delivery permitted us to study the impact of insulin
without affecting glycemia levels such as occurs with
systemic insulin delivery, easing difﬁculty in dissecting the
relative contributions of hyperglycemia and insulin’s tro-
phic properties (48). Prior studies using intranasal delivery
of insulin-like molecules such as IGF-1 have demonstrated
safety and efﬁcacy in experimental stroke (22). I-I delivery
in humans has led to improvements in memory (23) within
minimal impact on plasma glucose levels, which remain in
the euglycemic range (20,23). Although the use of I-I for the
management of systemic diabetes has been limited, in our
mouse cohorts, I-I was also associated with better mainte-
nance of body weight and improved mortality (Table 1).
Limitations of our results using I-I delivery in diabetic
mice must be acknowledged. Our results must be consid-
ered under the limitations of working with a murine
model, and the inability to achieve a long-term model of
murine type 1 diabetes with optimal glycemic management
as a suitable control group. The mouse cohorts were
subjected to intensive testing throughout their lifetime,
which may have led to stress impacting on behavioral
testing results. Diabetic CD1 mice developed sensory
behavioral changes earlier than has been observed in other
rodent models of diabetes, which may limit portability of
these ﬁndings to other models. It is also possible that
hypoglycemia may have impacted on sensorimotor testing;
the impact of hypoglycemia on the diabetic I-S and control
I-S cohort groups was anticipated but unavoidable. Distri-
bution of insulin within the diabetic nervous system may
differ from results obtained in nondiabetic mice examined
in our radiolabeling studies. In addition, although I-I–
obtained concentrations were higher in nervous system
tissues, tissue concentrations at later time points were not
different between I-I and S-I delivery, suggesting that
differences in systemic exposure and possibly different
metabolic rates for insulin may also play a role in our
results. Based on our studies, it is difﬁcult to develop a
more appropriate control group of diabetic mice with
long-term glycemic control based on the STZ-induced
diabetic model. However, our results also provide evi-
dence for potentially robust beneﬁts of insulin indepen-
dent of its actions on hyperglycemia. These results
support its role as an important neurotrophic factor in the
management of diabetic neuropathy. Our results support
the development of human I-I clinical trials for the preven-
tion and slowing of the development of DPN.
ACKNOWLEDGMENTS
This study was supported by an operating grant from the Al-
berta Heritage Foundation for Medical Research (AHFMR)
and the Canadian Diabetes Association (CDA). C.T. is a
Clinical Investigator of the Alberta Heritage Foundation for
Medical Research, and D.W.Z. is a Scientist of the Alberta
Heritage Foundation for Medical Research (AHFMR).
W.F. is the inventor of a patent for intranasal insulin
(Neurologic agents for nasal administration the brain.
World Intellectual Property Organization. PCT priority
date 5.12.89, WO 91/07947; 1991), a patent and technique
that has no goal of commercialization and therefore no
measurable ﬁnancial conﬂict of interest. Although W.F. is
an inventor on this patent about intranasal insulin, this
patent is wholly owned by Chiron/Novartis and, to the best
of our knowledge, the company has no intent to commer-
cialize intranasal insulin. None of the other co-authors have
any relationship with Chiron/Novartis. No other potential
conﬂicts of interest relevant to this article were reported.
REFERENCES
1. Boulton AJ, Ward JD: Diabetic neuropathies and pain. Clin Endocrinol
Metab 15:917–931, 1986
2. Zochodne DW: Diabetes mellitus and the peripheral nervous system:
manifestations and mechanisms. Muscle Nerve 36:144–166, 2007
3. Smith AG, Ramachandran P, Tripp S, Singleton JR: Epidermal nerve
innervation in impaired glucose tolerance and diabetes-associated neurop-
athy. Neurology 57:1701–1704, 2001
4. Toth C, Brussee V, Cheng C, Zochodne DW: Diabetes mellitus and the
sensory neuron. J Neuropathol Exp Neurol 63:561–573, 2004
5. Nelson D, Mah JK, Adams C, Hui S, Crawford S, Darwish H, Stephure D,
Pacaud D: Comparison of conventional and non-invasive techniques for
the early identiﬁcation of diabetic neuropathy in children and adolescents
with type 1 diabetes. Pediatr Diabetes 7:305–310, 2006
6. The Diabetes Control and Complications Trial Research Group: The effect
of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl
J Med 329:977–986, 1993
7. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional treat-
ment and risk of complications in patients with type 2 diabetes (UKPDS
33). Lancet 352:837–853, 1998
8. Calcutt NA, Freshwater JD, Mizisin AP: Prevention of sensory disorders in
diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment
with ciliary neurotrophic factor. Diabetologia 47:718–724, 2004
9. Yamagishi S, Ogasawara S, Mizukami H, Yajima N, Wada R, Sugawara A,
Yagihashi S: Correction of protein kinase C activity and macrophage
migration in peripheral nerve by pioglitazone, peroxisome proliferator
activated-gamma-ligand, in insulin-deﬁcient diabetic rats. J Neurochem
104:491–499, 2008
10. Pacher P, Obrosova IG, Mabley JG, Szabo C: Role of nitrosative stress and
peroxynitrite in the pathogenesis of diabetic complications. Emerging new
therapeutical strategies. Curr Med Chem 12:267–275, 2005
11. Estrella JS, Nelson RN, Sturges BK, Vernau KM, Williams DC, LeCouteur
RA, Shelton GD, Mizisin AP: Endoneurial microvascular pathology in feline
diabetic neuropathy. Microvasc Res 75:403–410, 2008
12. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M,
Sayed AA, Andrassy M, Schiekofer S, Schneider JG, Schulz JB, Heuss D,
Neundo ¨rfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M,
Haering Hu, Schleicher E, Kasper M, Stern DM, Arnold B, Nawroth PP:
Loss of pain perception in diabetes is dependent on a receptor of the
immunoglobulin superfamily. J Clin Invest 114:1741–1751, 2004
13. Toth C, Schmidt AM, Martinez JA, Song F, Ramji N, Brussee V, Liu W,
Durand J, Rong LL, Zochodne DW: RAGE and experimental diabetic
neuropathy. Diabetes 57:1002–1017, 2008
14. Calcutt NA, Jolivalt CG, Fernyhough P: Growth factors as therapeutics for
diabetic neuropathy. Curr Drug Targets 9:47–59, 2008
15. Sima AA, Kamiya H: Diabetic neuropathy differs in type 1 and type 2
diabetes. Ann N Y Acad Sci 1084:235–249, 2006
16. Toth C, Brussee V, Martinez JA, McDonald D, Cunningham FA, Zochodne
DW: Rescue and regeneration of injured peripheral nerve axons by
intrathecal insulin. Neuroscience 139:429–449, 2006
17. Toth C, Brussee V, Zochodne DW: Remote neurotrophic support of
epidermal nerve ﬁbres in experimental diabetes. Diabetologia 49:1081–
1088, 2006
18. White MF, Yenush L: The IRS-signaling system: a network of docking
proteins that mediate insulin and cytokine action. Curr Top Microbiol
Immunol 228:179–208, 1998
19. Leinninger GM, Backus C, Uhler MD, Lentz SI, Feldman EL: Phosphatidyl-
inositol 3-kinase and Akt effectors mediate insulin-like growth factor-I
neuroprotection in dorsal root ganglia neurons. FASEB J 18:1544–1546,
2004
20. Reger MA, Craft S: Intranasal insulin administration: a method for disso-
INTRANASAL INSULIN AND DIABETIC NEUROPATHY
944 DIABETES, VOL. 58, APRIL 2009ciating central and peripheral effects of insulin. Drugs Today (Barc)
42:729–739, 2006
21. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH: Delivery of insulin-like
growth factor-I to the rat brain and spinal cord along olfactory and
trigeminal pathways following intranasal administration. Neuroscience
127:481–496, 2004
22. Liu XF, Fawcett JR, Hanson LR, Frey WH: The window of opportunity for
treatment of focal cerebral ischemic damage with noninvasive intranasal
insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis 13:16–23, 2004
23. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B,
Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S:
Intranasal insulin improves cognition and modulates beta-amyloid in early
AD. Neurology 70:440–448, 2008
24. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive
method for measuring thermal nociception in cutaneous hyperalgesia 630.
Pain 32:77–88, 1988
25. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative
assessment of tactile allodynia in the rat paw. J Neurosci Methods
53:55–63, 1994
26. Sugimoto K, Murakawa Y, Sima AA: Expression and localization of insulin
receptor in rat dorsal root ganglion and spinal cord. J Peripher Nerv Syst
7:44–53, 2002
27. Xu QG, Li XQ, Kotecha SA, Cheng C, Sun HS, Zochodne DW: Insulin as an
in vivo growth factor. Exp Neurol 188:43–51, 2004
28. Fernyhough P, Willars GB, Lindsay RM, Tomlinson DR: Insulin and
insulin-like growth factor I enhance regeneration in cultured adult rat
sensory neurones. Brain Res 607:117–124, 1993
29. Zochodne DW, Verge VM, Cheng C, Sun H, Johnston J: Does diabetes target
ganglion neurones? Progressive sensory neurone involvement in long-term
experimental diabetes. Brain 124:2319–2334, 2001
30. Mahadev K, Wu X, Motoshima H, Goldstein BJ: Integration of multiple
downstream signals determines the net effect of insulin on MAP kinase vs.
PI 3	-kinase activation: potential role of insulin-stimulated H(2)O(2) 7. Cell
Signal 16:323–331, 2004
31. Huang TJ, Verkhratsky A, Fernyhough P: Insulin enhances mitochondrial
inner membrane potential and increases ATP levels through phosphoino-
sitide 3-kinase in adult sensory neurons. Mol Cell Neurosci 28:42–54, 2005
32. Huang TJ, Price SA, Chilton L, Calcutt NA, Tomlinson DR, Verkhratsky A,
Fernyhough P: Insulin prevents depolarization of the mitochondrial inner
membrane in sensory neurons of type 1 diabetic rats in the presence of
sustained hyperglycemia. Diabetes 52:2129–2136, 2003
33. Fernyhough P, Huang TJ, Verkhratsky A: Mechanism of mitochondrial
dysfunction in diabetic sensory neuropathy. J Peripher Nerv Syst 8:227–
235, 2003
34. Bruss MD, Arias EB, Lienhard GE, Cartee GD: Increased phosphorylation
of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in response to
insulin or contractile activity. Diabetes 54:41–50, 2005
35. Yao R, Cooper GM: Requirement for phosphatidylinositol-3 kinase in the
prevention of apoptosis by nerve growth factor. Science 267:2003–2006,
1995
36. Viard P, Butcher AJ, Halet G, Davies A, Nu ¨rnberg B, Heblich F, Dolphin AC:
PI3K promotes voltage-dependent calcium channel trafﬁcking to the
plasma membrane. Nat Neurosci 7:939–946, 2004
37. Jones DM, Tucker BA, Rahimtula M, Mearow KM: The synergistic effects of
NGF and IGF-1 on neurite growth in adult sensory neurons: convergence
on the PI 3-kinase signaling pathway. J Neurochem 86:1116–1128, 2003
38. Ogata T, Iijima S, Hoshikawa S, Miura T, Yamamoto S, Oda H, Nakamura
K, Tanaka S: Opposing extracellular signal-regulated kinase and Akt
pathways control Schwann cell myelination. J Neurosci 24:6724–6732,
2004
39. Maurel P, Salzer JL: Axonal regulation of Schwann cell proliferation and
survival and the initial events of myelination requires PI 3-kinase activity.
J Neurosci 20:4635–4645, 2000
40. Liang G, Cline GW, Macica CM: IGF-1 stimulates de novo fatty acid
biosynthesis by Schwann cells during myelination. Glia 55:632–641, 2007
41. Zheng WH, Kar S, Quirion R: Insulin-like growth factor-1-induced phos-
phorylation of transcription factor FKHRL1 is mediated by phosphatidyl-
inositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth
factor-1-induced survival of cultured hippocampal neurons. Mol Pharma-
col 62:225–233, 2002
42. Walton M, Woodgate AM, Muravlev A, Xu R, During MJ, Dragunow M:
CREB phosphorylation promotes nerve cell survival. J Neurochem 73:
1836–1842, 1999
43. Lonze BE, Riccio A, Cohen S, Ginty DD: Apoptosis, axonal growth defects,
and degeneration of peripheral neurons in mice lacking CREB. Neuron
34:371–385, 2002
44. Hetman M, Cavanaugh JE, Kimelman D, Xia Z: Role of glycogen synthase
kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neu-
rosci 20:2567–2574, 2000
45. Pap M, Cooper GM: Role of glycogen synthase kinase-3 in the phosphati-
dylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273:19929–
19932, 1998
46. Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol
2:769–776, 2001
47. Grimes CA, Jope RS: CREB DNA binding activity is inhibited by glycogen
synthase kinase-3 beta and facilitated by lithium. J Neurochem 78:1219–
1232, 2001
48. Tomlinson DR, Gardiner NJ: Glucose neurotoxicity. Nat Rev Neurosci
9:36–45, 2008
49. Kennedy JM, Zochodne DW: Experimental diabetic neuropathy with
spontaneous recovery: is there irreparable damage? Diabetes 54:830–837,
2005
G. FRANCIS AND ASSOCIATES
DIABETES, VOL. 58, APRIL 2009 945